Ultragenyx Pharmaceutical (RARE) Q2 2021 Earnings Report

1 Followers

MX:RARE Q2 2021 EPS Results

Actual EPS: -MXN 33.71
Consensus EPS: -MXN 24.64
Beat/Miss: Missed by -MXN 9.07
One Year Ago EPS: MXN 7.64

MX:RARE Q2 2021 Revenue Results

Actual Revenue: MXN 1.62B
Expected Revenue: MXN 1.60B
Beat/Miss: Beat by +MXN 20.66M
YoY Revenue Growth: +40.94%

Earnings Announcement Details

Quarter: Q2 2021
Date: 08/02/2021
Time: After Close
Conference Call: Monday, August 2, 2021

MX:RARE Upcoming Earnings

Ultragenyx Pharmaceutical's next earnings date is estimated for February 18, 2027, based on past reporting schedules.

Q2 2021 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2021 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2021 Earnings Call Summary

No earnings call summary is available for this earnings event.

MX:RARE Earnings History

MX:RARE earnings history
Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Press Release
Feb 18, 2027	2026 (Q4)	40.81-	-24.03	―	―
Nov 03, 2026	2026 (Q3)	-20.49-21.61	-33.71	35.91% (+12.11)
Aug 04, 2026	2026 (Q2)	-23.13-16.76	-21.79	23.08% (+5.03)
May 05, 2026	2026 (Q1)	-27.71-34.27	-29.24	-17.20% (-5.03)
Feb 12, 2026	2025 (Q4)	-20.36-24.03	-25.89	7.19% (+1.86)
Nov 04, 2025	2025 (Q3)	-22.98-33.71	-26.08	-29.29% (-7.64)
Aug 05, 2025	2025 (Q2)	-24.16-21.79	-28.31	23.03% (+6.52)
May 06, 2025	2025 (Q1)	-29.76-29.24	-37.81	22.66% (+8.57)
Feb 13, 2025	2024 (Q4)	-24.36-25.89	-28.31	8.55% (+2.42)
Nov 05, 2024	2024 (Q3)	-27.64-26.08	-41.53	37.22% (+15.46)
Aug 01, 2024	2024 (Q2)	-30.94-28.31	-41.91	32.44% (+13.60)
May 02, 2024	2024 (Q1)	-32.54-37.81	-43.4	12.88% (+5.59)
Feb 15, 2024	2023 (Q4)	-31.79-28.31	-40.23	29.63% (+11.92)
Nov 02, 2023	2023 (Q3)	-38.69-41.53	-65.19	36.29% (+23.65)
Aug 03, 2023	2023 (Q2)	-38.93-41.91	-42.09	0.44% (+0.19)
May 04, 2023	2023 (Q1)	-37.10-43.40	-40.79	-6.39% (-2.61)
Feb 16, 2023	2022 (Q4)	-39.77-40.23	-33.34	-20.67% (-6.89)
Nov 02, 2022	2022 (Q3)	-33.73-65.19	-20.12	-224.07% (-45.07)
Jul 28, 2022	2022 (Q2)	-32.59-42.09	-33.71	-24.86% (-8.38)
May 05, 2022	2022 (Q1)	-33.17-40.79	-37.81	-7.88% (-2.98)
Feb 10, 2022	2021 (Q4)	-25.59-33.34	-6.89	-383.78% (-26.45)
Nov 02, 2021	2021 (Q3)	-25.96-20.12	-21.05	4.42% (+0.93)
Aug 02, 2021	2021 (Q2)	-24.64-33.71	7.64	-541.46% (-41.35)
May 04, 2021	2021 (Q1)	―-37.81	-38.18	0.98% (+0.37)
Feb 11, 2021	2020 (Q4)	―-6.89	-30.17	77.16% (+23.28)
Oct 27, 2020	2020 (Q3)	―-21.05	-36.51	42.35% (+15.46)
Jul 30, 2020	2020 (Q2)	―7.64	-32.04	123.84% (+39.67)
May 06, 2020	2020 (Q1)	―-38.18	-33.9	-12.64% (-4.28)
Feb 13, 2020	2019 (Q4)	―-30.17	-32.22	6.36% (+2.05)
Nov 05, 2019	2019 (Q3)	―-36.51	-32.41	-12.64% (-4.10)
Aug 01, 2019	2019 (Q2)	―-32.04	-19.74	-62.26% (-12.29)
May 06, 2019	2019 (Q1)	―-33.90	11.55	-393.55% (-45.45)
Feb 19, 2019	2018 (Q4)	―-32.22	-35.2	8.47% (+2.98)
Nov 05, 2018	2018 (Q3)	―-32.41	-34.83	6.95% (+2.42)
Aug 02, 2018	2018 (Q2)	―-19.74	-32.04	38.37% (+12.29)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed

Ultragenyx Pharmaceutical earnings date